Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update

OBJECTIVE: Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a cornerstone therapy, many patients are not achieving their risk-specific low-density lipoprotein cholesterol (LDL-C) goals. The proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies h...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaddoura, Rasha, Orabi, Bassant, Salam, Amar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470150/
https://www.ncbi.nlm.nih.gov/pubmed/32939318
http://dx.doi.org/10.1080/21556660.2020.1801452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470150/
https://www.ncbi.nlm.nih.gov/pubmed/32939318
http://dx.doi.org/10.1080/21556660.2020.1801452

Ejemplares similares